tact Bruch membrane and gain access to the eye. However, AMD is a late-onset disease, and in these older individuals, the Bruch membrane may not be intact. Therefore, we would welcome more substantial, long-term data from randomized trials to support that CETP inhibition does not cause AMD.

Liv Tybjærg Nordestgaard, MD, PhD  
Børge Grønne Nordestgaard, MD, DMSc  
Anne Tybjærg-Hansen, MD, DMSc

Author Affiliations: Department of Clinical Biochemistry, Section for Molecular Genetics, Rigshospitalet, Copenhagen, Denmark (L. T. Nordestgaard, Tybjærg-Hansen); Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark (B. G. Nordestgaard); Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (B. G. Nordestgaard, Tybjærg-Hansen).

Corresponding Author: Anne Tybjærg-Hansen, MD, DMSc, Department of Clinical Biochemistry, Section for Molecular Genetics, Rigshospitalet, Blegdamsvej 9, Copenhagen DK-2100, Denmark (anne.tybjaerg.hansen@regionh.dk).

Published Online: June 1, 2022. doi:10.1001/jamacardio.2022.1279

Conflict of Interest Disclosures: Dr B. Nordestgaard has received personal fees from Akcea, Amgen, AstraZeneca, Denka, Esperion, Kowa, Novartis, Novo Nordisk, Regeneron, Sanofi, and Silence Therapeutics. Dr Tybjærg-Hansen has received personal fees from Amgen, Akcea, AstraZeneca, Draupnir Bio, Novartis, Regeneron, Sanofi, and Silence Therapeutics. No other disclosures were reported.


